Malignant Peripheral Nerve Sheath Tumors Clinical Trial
Official title:
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01661283 -
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
|
Phase 2 | |
Completed |
NCT03433183 -
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
|
Phase 2 | |
Active, not recruiting |
NCT02584647 -
PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03880123 -
Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
|
Phase 1 | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Terminated |
NCT00427583 -
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
|
Phase 2/Phase 3 | |
Recruiting |
NCT05245500 -
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
|
Phase 1/Phase 2 | |
Recruiting |
NCT03618381 -
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
|
Phase 1 | |
Active, not recruiting |
NCT03989596 -
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
|
Phase 2 | |
Recruiting |
NCT04897321 -
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
|
Phase 1 | |
Active, not recruiting |
NCT04483778 -
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
|
Phase 1 | |
Not yet recruiting |
NCT06277154 -
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Active, not recruiting |
NCT03651375 -
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
|
Phase 2 | |
Recruiting |
NCT03611868 -
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05985161 -
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
|
Phase 2 |